Pharmaceutical Executive-10-01-2007

Trending on PharmExec

Roundup: Gilead Acquires Oral IL-23R Inhibitor From PepStar for $1.275 Billion, Zymeworks Licenses DLL3-Targeting T Cell Engager to Roche

FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B

FDA Grants Ultomiris Accelerated Approval in the U.S. for Adults with Primary Immunoglobulin A Nephropathy

Pharmaceutical Executive Daily: FDA Grants Ultomiris Accelerated Approval in the U.S.

Roundup: Alcon Acquires Neurotech and Encelto, Ai Proteins Enters Research Collaboration and License Agreement with Astellas Pharma